Biosceptre’s collaboration with Garvan on antibody development and optimisation continues to progress. This work has yielded promising monoclonal antibodies through immunization of animals. However, direct therapeutic use of such monoclonal antibodies is not possible because of the immunogenicity of mouse monoclonals in humans.
SAB member and grant co-investigator, Sir Gregory Winter, highlights the potential of humanized and affinity-matured antibodies for Biosceptre:
“Garvan’s innovative protein design work uses x-ray crystallography, phage display and mutagenesis to humanize anti-peptide antibodies, and to modulate affinity. This may provide novel antibodies for Biosceptre, and in particularly for our BRiDGECAR™ development program, which requires fine-tuning of affinity and structural characterisation of the components to achieve optimal efficacy.
We are grateful for the support of this program from the National Health and Medical Research Council NHMRC Development Grant Program.